Cargando…
Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors
Radiotherapy is routinely used as a neoadjuvant, adjuvant or palliative treatment in various cancers. There is significant variation in clinical response to radiotherapy with or without traditional chemotherapy. Patients with a good response to radiotherapy demonstrate better clinical outcomes unive...
Autores principales: | Wanigasooriya, Kasun, Tyler, Robert, Barros-Silva, Joao D., Sinha, Yashashwi, Ismail, Tariq, Beggs, Andrew D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281073/ https://www.ncbi.nlm.nih.gov/pubmed/32443649 http://dx.doi.org/10.3390/cancers12051278 |
Ejemplares similares
-
Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer
por: Elfiky, Aymen A, et al.
Publicado: (2011) -
The phosphatidylinositol-3 kinase/mTOR pathway: new agents
por: Arteaga, CL
Publicado: (2011) -
Can phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibition ERase them all?
por: Meyer, Dominique S, et al.
Publicado: (2010) -
The mammalian target of rapamycin (mTOR) kinase mediates haloperidol-induced cataleptic behavior
por: Ramírez-Jarquín, Uri Nimrod, et al.
Publicado: (2020) -
Everolimus Reverses Palbociclib Resistance in ER+ Human Breast Cancer Cells by Inhibiting Phosphatidylinositol 3-Kinase(PI3K)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway
por: Chen, Lin, et al.
Publicado: (2019)